Evidence

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

April 18, 2019

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). AUTHORS: Floris H. Groenendijk, Tina Treece, Erin Yoder, Paul Baron, Peter Beitsch, William Audeh, Winand N. M. Dinjens, Rene Bernards & Pat Whitworth ABSTRACT: Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classified clinically as Luminal-type. We showed previously that molecular subtyping using the 80-gene signature (80-GS) reclassified a…

Read more

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

August 4, 2013

PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Floris H. Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards ABSTRACT: It is well established that only estrogen receptor (ER)-positive tumors benefit from hormonal therapies. We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor α (ERα), but fails to respond to hormonal therapy due…

Read more